ClinicalTrials.gg
RecruitingNCT06074614NEURON-PDUpdated Dec 20, 2024

Neural Control of Breathing in Parkinson's Disease

An observational study in Parkinson Disease, sponsored by Radboud University Medical Center. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-20.

Sponsored by Radboud University Medical Center · Observational

How we know

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 6 months ago, but the record still lists the study as recruiting.
  • Started Oct 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
30
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies in Parkinson Disease by Radboud University Medical Center — 6 open to participants now, 12 under way, 1 of them phase 3. Parkinson Disease · Radboud University Medical Center.

Planned enrollment
10th of 12
30 · median 133
Started
2023
with 6 others
Observational
12 of 34
2 open now
Primary completion
2025-05
later than 3 of 11 live
Registered
28th of 34
by date

Among the 34 studies in Parkinson Disease by Radboud University Medical Center, this one is the 10th largest by planned enrollment of the 12 observational ones that give a count, is one of 7 that started in 2023, is one of 12 observational ones, reaches primary completion later than 3 of the 11 other live ones, and was the 28th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

6 of the 34 studies in Parkinson Disease by Radboud University Medical Center are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Parkinson Disease by Radboud University Medical Center, or all of them as a file.
02

Study summary

Breathing is a complex process, which can be controlled through voluntary command or neural control. Parkinson's disease (PD) is a progressive neurological disorder. Many individuals with PD experience respiratory problems, such as coughing difficulties or shortness of breath. Changes in neural control of breathing could be part of the reason of these respiratory problems. This study will measure whether neural control of breathing is impaired in individuals with PD compared to healthy individuals.

Read the detailed description

Rationale: Parkinson's disease (PD) is a progressive neurological disorder, characterised by loss of dopaminergic neurons. Respiratory dysfunction is common in patients with PD and can lead to pneumonia, which is a common cause of death in PD. However, the exact mechanism of respiratory dysfunction in PD is unknown. The complex process of neural control of breathing may be involved, but this is understudied. This is partly caused by methodological limitations to quantify neural control of breathing. In this study, we will use respiratory neurophysiological methods to determine whether neural control of breathing is impaired in Parkinson's disease. These techniques are hypercapnic ventilatory response, respiratory related evoked potentials and transcranial magnetic stimulation. This study will test the hypothesis that the neural control of breathing is impaired in individuals with PD compared to healthy subjects.

Objective: Primary Objective: To identify disease (Parkinson's disease) specific alterations in neural control of breathing by using respiratory neurophysiological techniques.

Study design: Exploratory cross-sectional study.

Study population: Healthy subjects (n=15) and patients with Parkinson's disease (n=15) >18 years old.

Main study parameters/endpoints:

  • Hypercapnic ventilatory response curve (HCVR): HCVR will be determined using the CO2-rebreathing technique.
  • Respiratory related evoked potential (RREP): RREP is a measure of cerebral cortical activity elicited by a short inspiratory occlusion.
  • Transcranial magnetic stimulation (TMS) diaphragm: TMS is an established tool for investigating the cortical excitability related to breathing.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The risk of this study for the participants is negligible. Subjects do not directly benefit from participating in this study. The scientific benefit of this study is to achieve a better understanding of the neural control of breathing in Parkinson's disease. The outcomes of this study may give rise to future new treatments in Parkinson's disease. The burden of the separate study procedures is relatively small: there are no invasive procedures and patients continue their medication as usual. However, the total time of the visit and the collective burden of the experiments may be perceived as strenuous. Therefore, subjects will be explicitly informed about this aspect of the study, and enough breaks will be scheduled in the program.

03

Conditions studied

  • Parkinson Disease

Keywords

  • Parkinson's disease
  • Respiratory dysfunction
  • Neural control of breathing
  • Transcranial magnetic stimulation
  • Hypercapnic ventilatory response
  • Respiratory related evoked potential
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Healthy participants: volunteers. Age- and sex-matched to the participants with Parkinson's disease.

Participants with Parkinson's disease: recruited through the outpatient registry at the Radboud University Medical Center that have approved contact for research purposes.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy subjects: competent adult (>18 years) volunteers
  • Patients: adult (\<18 years) patients with Parkinson's disease, clinically confirmed by a movement disorder specialised neurologist with Hoehn and Yahr staging 1 to 3
  • Willingness and ability to understand nature and content of the study
  • Ability to participate and comply with study requirements

Exclusion criteria

Exclusion Criteria:

  • Healthy subjects: previous or ongoing diseases of the central nervous system
  • Patients: previous or ongoing diseases of the central nervous system, other than Parkinson's disease
  • History of or current psychiatric treatment
  • History of or current brain surgery or epilepsy, unclusing deep brain stimulation
  • Neuromuscular disorders
  • Pre-existing pulmonary disease, such as , asthma or pulmonary fibrosis
  • TMS incompatibility (metal parts in head or neck, skin allergies)
  • Implanted cardiac pacemaker or defibrillator, neurostimulator, cochlear implant or medical infusion device
  • Large or ferromagnetic metal parts in the head (exept for a dental wire)
  • Pregnancy
  • Smoking
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
30 participants (estimated)
Patient registry
No

Groups and cohorts

  • Parkison's disease

    Participants with clinically confirmed Parkinson's disease, Hoehn and Yahr stage 1 to 3.

    Diagnostic Test: Hypercapnic ventilatory response · Diagnostic Test: Respiratory related evoked potential · Diagnostic Test: Transcranial magnetic stimulation

  • Healthy controls

    Participants without Parkinson's disease.

    Diagnostic Test: Hypercapnic ventilatory response · Diagnostic Test: Respiratory related evoked potential · Diagnostic Test: Transcranial magnetic stimulation

Interventions

  • Diagnostic testHypercapnic ventilatory response

    Control of breathing is predominantly regulated by feedback of the central chemoreceptors. All chemoreceptors are sensitive to changes in partial pressure of carbon dioxide and via acid-base reactions to hydrogen concentration. The hypercapnic ventilatory response test shows the relationship between end-tidal PCO2 and the resulting minute ventilation.

  • Diagnostic testRespiratory related evoked potential

    The RREP is a measure of cerebral cortical activity elicited by short inspiratory occlusion or breathing against inspiratory resistive loads and quantifies the initial arrival and further processing of sensory afferent respiratory information in the cortex.

  • Diagnostic testTranscranial magnetic stimulation

    Transcranial magnetic stimulation of the diaphragm is an established tool for investigating the cortical excitability related to breathing. TMS will be delivered over the vertex using a magnetic stimulator and a 110mm double cone coil.

06

What researchers measure

Primary outcomes

  1. Hypercapnic ventilatory response curve

    Sensitivity slope of the ventilation increase per unit increase in PetCO2, as measured with a rebreathing technique.

    Time frame: baseline - during the test

  2. Respiratory related evoked potential

    A measure of cerebral cortical activity elicited by a short inspiratory occlusion, expressed in the presence, latency and amplitude of components Nf, P1, N1, P2 and P3.

    Time frame: baseline - during the test

  3. Transcranial magnetic stimulation

    Interstimulus interval curves, using a conditioning stimulus at 80% and a test stimulus at 125%.

    Time frame: baseline - during the test

Secondary outcomes

  1. FVC

    Forced vital capacity.

    Time frame: baseline - during the test

  2. FEV1

    Forced expiratory volume in 1 second.

    Time frame: baseline - during the test

  3. MIP

    Maximal inspiratory pressure.

    Time frame: baseline - during the test

  4. MEP

    Maximal expiratory pressure.

    Time frame: baseline - during the test

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2023 (actual). Primary completion is estimated for May 2025, 19 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2023
First posted
Oct 10, 2023
StartActual
Oct 30, 2023
Primary completionEst.
May 2025
CompletionEst.
May 2025
Last update
Dec 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06074614
Responsible party
Sponsor
First posted
Oct 10, 2023
Start date
Oct 30, 2023
Primary completion
May 2025 (estimated)
Completion
May 2025 (estimated)
Last update
Dec 20, 2024

Study contacts

Jonne Doorduin, PhD
Contact
jonne.doorduin@radboudumc.nl
+31243611111
Jonne Doorduin, PhD
principal investigator · Radboud University Medical Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion